azacitidine
New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022
Report From ASH 2019: Oral Azacitidine Formulation Extends First Remissions in AML
ORLANDO, FLA.—A novel oral formulation of azacitidine produced a highly significant improvement in overall ...
DECEMBER 19, 2019
Understanding Why Some MDS Resists Azacitidine Treatment
Patients with myelodysplastic syndrome who are resistant to azacitidine (AZA) have quiescent bone marrow ...
NOVEMBER 6, 2017
Load more